Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again)

被引：19

作者：

Deighton, C. M. ^{[1
]}

George, E.

Kiely, P. D. W.

Ledingham, J.

Luqmani, R. A.

Scott, D. G. I.

机构：

[1] Derbyshire Royal Infirm, Dept Rheumatol, Derby DE1 2QY, England

[2] Arrowe Pk Hosp, Dept Rheumatol, Wirral, Merseyside, England

[3] St Georges Healthcare, NHS Trust, Dept Rheumatol, London, England

[4] Queen Alexandra Hosp, Dept Rheumatol, Portsmouth, Hants, England

[5] Nuffield Orthopaed Ctr, Dept Rheumatol, Oxford OX3 7LD, England

[6] Norfolk & Norwich Univ Hosp, Dept Rheumatol, Norwich, Norfolk, England

来源：

RHEUMATOLOGY | 2006年 / 45卷 / 06期

关键词：

D O I：

10.1093/rheumatology/kel053

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：649 / 652

页数：4

共 29 条

[1]

Aletaha D, 2004, ANN RHEUM DIS, V63, P111

[2] Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states [J].

Aletaha, D ;

Ward, MM ;

Machold, KP ;

Nell, VPK ;

Stamm, T ;

Smolen, JS .

ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2625-2636

[3] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[4] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[5]

*BRIT SOC RHEUM, 2001, GUID PRESCR TNF ALPH

[6] C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis - Defining subtypes of nonresponse and subsequent response to etanercept [J].

Buch, MH ;

Seto, Y ;

Bingham, SJ ;

Bejarano, V ;

Bryer, D ;

White, J ;

Emery, P .

ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :42-48

[7] True infliximab resistance in rheumatoid arthritis:: a role for lymphotoxin α? [J].

Buch, MH ;

Conaghan, PG ;

Quinn, MA ;

Bingham, SJ ;

Veale, D ;

Emery, P .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) :1344-1346

[8]

Emery P, 1997, J RHEUMATOL, V24, P1436

[9] Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 [J].

Furst, DE ;

Breedveld, FC ;

Kalden, JR ;

Smolen, JS ;

Burmester, GR ;

Bijlsma, JWJ ;

Dougados, M ;

Emery, P ;

Keystone, EC ;

Klareskog, L ;

Mease, PJ .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :2-14

[10] Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes [J].

Genovese, MC ;

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Cannon, GW ;

Spencer-Green, G ;

Finck, BK .

ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1443-1450

← 1 2 3 →